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A NEW GOVERNANCE APPROACH TO REGULATING HUMAN 
GENOME EDITING 
John M. Conley, Arlene M. Davis, Gail E. Henderson, Eric T. 
Juengst, Karen M. Meagher, Rebecca L. Walker, Margaret 
Waltz, & Jean Cadigan∗  
For years, genomic medicine—medicine based on the growing 
understanding of the genetic contribution to many diseases and 
conditions—has been hailed as the future of medical treatment, but 
it has thus far had limited effect on day-to-day medical practice. 
The ultimate goal of genomic medicine has always been the ability 
not just to identify dangerous gene mutations, but to fix them. Now 
CRISPR and related genome-editing technologies may have the 
potential to provide a safe and effective way to repair dangerous 
mutations. 
In the wake of ethically dubious experiments with human 
embryos in China, the international governance of human genome 
editing is emerging as an urgent topic for scientists, regulators, 
and the public. Efforts to develop a governance model are 
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underway at national and international levels. These efforts are the 
subject of multiple initiatives by national and international health 
and science organizations and are topics of discussion at scientific 
conferences, summits, and meetings. 
This Article reports on the Authors’ multi-year, 
interdisciplinary project to identify and investigate the practical, 
ethical, and policy considerations that are emerging as the 
greatest concerns about human genome editing, and ultimately to 
develop policy options. The project involves monitoring the 
discussions of groups, both government-sponsored and private, 
that are considering how genome editing should be governed; 
observing conferences where the topic is discussed; analyzing 
emerging policy reports by national and international bodies; and 
interviewing a wide range of stakeholders, including scientists, 
ethicists, and those who make and comment on public policy. The 
Article identifies several stakeholder concerns that are especially 
prominent in the research to date and begins to explore the 
implications of these concerns for alternative models of governance. 
There are current indications that, for practical purposes, a focus on 
“soft,” hybrid forms of governance based on networks of multiple 
public and private stakeholders may turn out to be the most 
promising course to pursue. The “new governance” paradigm 
developed in the corporate and financial sectors offers a useful 
model for understanding the dynamics of this approach. 
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I. INTRODUCTION 
The first reports of human genome editing—altering the 
genetic code of a human being—in nonviable embryos in China in 
2015 ignited a wave of ongoing policy discussions about the 
appropriate limits of such research in today’s globalized scientific 
environment.1 Chinese scientist He Jiankui’s 2018 claim to have 
edited the embryonic genome of living twin baby girls2 (for which 
he was reportedly imprisoned for “illegal medical practices”),3 
followed by a Russian geneticist’s announcement of similar plans,4 
                                                 
 1 See Carolyn Brokowski, Do CRISPR Germline Ethics Statements Cut It?, 1 CRISPR 
J. 115, 115–23 (2018), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694771/ 
[https://perma.cc/WYQ9-CTN6]. 
 2 Dennis Normile, CRISPR Bombshell: Chinese Researcher Claims to 
Have Created Gene-Edited Twins, SCI. (Nov. 26, 2018), 
https://www.sciencemag.org/news/2018/11/crispr-bombshell-chinese-researcher-
claims-have-created-gene-edited-twins [https://perma.cc/JYC7-DSH9]. 
 3 Dennis Normile, Chinese Scientist Who Produced Genetically Altered 
Babies Sentenced to 3 Years in Jail, SCI. (Dec. 30, 2019), 
https://www.sciencemag.org/news/2019/12/chinese-scientist-who-produced-
genetically-altered-babies-sentenced-3-years-jail [https://perma.cc/7FCZ-QT2B]. 
 4 See Jon Cohen, Embattled Russian Scientist Sharpens Plans to Create 
Gene-Edited Babies, SCI. (OCT. 21, 2019), 
https://www.sciencemag.org/news/2019/10/embattled-russian-scientist-
sharpens-plans-create-gene-edited-babies [https://perma.cc/B5M9-GPTC]. The 
Russian scientist has not abandoned his plans, even after the controversy in 
China. See Michael LePage, Russian Scientist Still Aims to Make CRISPR 
Babies Despite the Risks, NEW SCIENTIST (Sept. 3, 2020), 
https://www.newscientist.com/article/2253688-russian-biologist-still-aims-to-
make-crispr-babies-despite-the-risks/ [https://perma.cc/FWM8-4A63]. 
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gave new urgency to those discussions.5 Current human genome 
editing governance consists of a patchwork of national, local, and 
institutional regulations and scientific and professional policy 
statements; some of those statements aim at international status, 
but few offer specific prescriptions for oversight.6 In the wake of 
the developments in China, efforts to harmonize this patchwork 
across jurisdictions and stakeholder groups have been the topic of 
multiple conferences, declarations, and publications, involving 
both scientists and policymakers. 
The Authors are engaged in a multi-year, interdisciplinary 
project to identify and investigate the practical, ethical, and policy 
considerations that are emerging as the greatest concerns about 
human genome editing, and ultimately to develop policy options 
for governance of this rapidly evolving science. The project uses 
the term governance rather than such alternatives as “government,” 
“regulation,” or “control” in order to be open to all oversight 
possibilities, in whatever form and from all possible sources of 
authority or influence. The project involves, among other research, 
monitoring the publicly accessible discussions of groups, both 
government-sponsored and private, that are considering how 
genome editing should be governed; observing conferences where 
the topic is discussed; analyzing emerging policy reports by 
national and international bodies; and interviewing a wide range of 
stakeholders, including scientists, ethicists, and those who make 
and comment on public policy. This Article identifies several 
stakeholder concerns that are especially prominent in the research 
to date and begins to explore the implications of these concerns for 
alternative models of governance. There are current indications 
that, for practical purposes, a focus on “soft,” hybrid forms of 
governance based on networks of multiple public and private 
stakeholders may turn out to be the most promising course to 
pursue.7 The “new governance” paradigm developed in the 
                                                 
 5 See Henry T. Greely, He Jiankui, Embryo Editing, CCR5, the London 
Patient, and Jumping to Conclusions, STAT (Apr. 15, 2019), 
https://www.statnews.com/2019/04/15/jiankui-embryo-editing-ccr5/ [https://per
ma.cc/HTU3-R7XT]. 
 6 See Brokowski, supra note 1. 
 7 See infra Part VI.C. 
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corporate and financial sectors offers a useful model for 
understanding the dynamics of this approach.8 
Part II of the Article describes the basic science of genome 
editing. Part III explains the various categories of genome editing 
and the need for governance across these categories. Part IV 
presents the research project in more detail and reports some of its 
significant findings to date. Part V uses these findings to analyze 
the possible approaches to genome editing governance that are 
being proposed, with specific reference to the concerns that seem 
to be motivating the various proposals. Part VI evaluates each 
approach in terms of its potential to meet these concerns, and Part 
VII offers a brief conclusion. 
II.   GENOME EDITING TECHNOLOGY 
A. Genes and the Genome 
An organism’s genome is the entirety of the DNA in its cells.9 
Genes are the subset of the genome that perform the function of 
building, or coding for, proteins.10 The details of the 
protein-building function depend on the specific DNA that is 
present in the organism’s cells. DNA, the chemical responsible for 
inheritance, is a double-stranded molecule containing long strings 
of four chemicals called bases (abbreviated A, T, C, and G); 
because DNA is double-stranded, they appear as base pairs, one on 
each strand. The order of the base pairs in an organism’s genome is 
its DNA sequence. It is this sequence that determines what proteins 
an organism’s cells build, and when. Genes account for only a 
                                                 
 8 See generally John M. Conley & Cynthia A. Williams, Global Banks as 
Global Sustainability Regulators?: The Equator Principles, 33 J.L. & POL’Y 542 
(2011) (presenting case study of new governance approach to global banking 
problem). 
 9 The brief overview of genome editing in this section is based on John M. 
Conley, Introduction: A Lawyer’s Guide to Crispr, 97 N.C. L. REV. 1041, 1042–
47 (2019). Readers interested in more detail about the underlying science should 
consult that reference and the sources cited therein. 
 10 The distinction between genome and genes, and thus between genome 
editing and gene editing, is important to scientists but rarely of interest to other 
audiences. The policy literature tends to use genome and gene editing 
interchangeably, as the authors do on occasion in this Article. 
112 N.C. J.L. & TECH. [VOL. 22: 2 
small portion of the DNA in the genome.11 Other portions of the 
genome have regulatory functions, such as controlling when 
particular genes switch on and off, while other large portions of the 
genome have no currently known function.12 RNA is a 
single-stranded cousin of DNA that performs many functions in 
the cell.13 By coding for proteins in particular ways, DNA provides 
a template for life; it determines the identities of different species, 
and influences some of the differences between individuals within 
a species. Some DNA variants, or mutations—changes in the 
sequence from the organism’s usual pattern—can contribute to, or, 
in some cases, cause a disease or disability. Still, other variants 
may be beneficial in the sense offering special protections from 
disease or disability. 
B. CRISPR Gene Editing 
 To edit the genome is to intervene in a cell and change its 
DNA sequence. This can be done in a variety of ways: by excising 
one or more bases, by turning particular bases on or off, or even by 
substituting one sequence for another. This latter possibility 
represents the ultimate promise of genomic medicine: the ability 
not just to identify dangerous gene mutations, but to fix them, to go 
into a patient’s cells and change a dangerous DNA sequence to a 
non-pathogenic one. 
Gene editing technologies have been around for more than 
twenty-five years. Earlier approaches include Zinc-Finger 
Nucleases (ZFNs) and Transcription Activator-Like Effector 
Nucleases (TALENs).14 The current focus is on a technology called 
CRISPR, which stands for Clustered Regularly Interspaced 
                                                 
 11 See Jonathan Henninger, The 99 Percent . . . of the Human Genome, HARV. 
UNIV.: SCI. IN THE NEWS (Oct. 1, 2012), http://sitn.hms.harvard.edu/ 
flash/2012/issue127a/ [https://perma.cc/ECM6-4HV9]. 
 12 See id. 
 13 See Carl Zimmer, Breakthrough DNA Editor Born of Bacteria, QUANTA 
MAG. (Feb. 6, 2015), https://www.quantamagazine.org/crispr-natural-history-in-
bacteria-20150206/ [https://perma.cc/3Q9J-D2CE]. 
 14 See Conley, supra note 9, at 1046. 
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Palindromic Repeats.15 These are short repeating sequences in the 
DNA of E. coli and other bacteria that were discovered by 
Japanese researchers in the 1980s.16 Their function was unknown 
for about twenty years, until food scientists using bacteria to make 
yogurt figured out that they are part of the bacteria’s immune 
system.17 These scientists realized that the CRISPR sequences 
resemble the DNA of viruses.18 In fact, the CRISPR sequences are 
taken from viral DNA that the bacteria has captured during past 
viral invasions.19 When a new viral attack occurs, the bacteria’s 
immune system compares the virus’s genetic material to the 
sequences stored in CRISPR; if it detects a match, it launches 
enzymes (a class of proteins that facilitate chemical reactions) to 
cut up the incoming viral DNA and repel the invasion.20 
The bacterial CRISPR sequences are always accompanied by 
genes that code for enzymes that can cut DNA.21 The original 
CRISPR scientists called them Cas (for CRISPR-associated) 
genes.22 Later research revealed that when viruses invade a 
bacterial cell, the CRISPR regions produce single-stranded RNA 
versions of the viral DNA sequences that it has captured and 
stored.23 These RNA sequences are cradled by the Cas enzymes 
and carried around the cell.24 When an RNA sequence encounters 
its viral DNA counterpart it latches on and the Cas enzyme cuts the 
DNA, which stops the virus from replicating.25 
Current CRISPR gene-editing technology mimics this natural 
process. Researchers at the University of California-Berkeley 
                                                 
 15 Brad Plumer et al., A Simple Guide to CRISPR, One of the Biggest 
Science Stories of the Decade, VOX (Dec. 27, 2018), 
https://www.vox.com/2018/7/23/17594864/crispr-cas9-gene-editing 
[https://perma.cc/N6AM-MBMA]. 
 16 Id. 
 17 Id. 
 18 Id. 
 19 Id. 
 20 Id. 
 21 Plumer et al., supra note 15. 
 22 Id. 
 23 Id. 
 24 Id. 
 25 Id. 
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chose a pair of Cas enzymes called Cas9.26 They supplied the 
enzymes with the RNA counterpart of the genetic sequence they 
wanted to edit—the target gene.27 The RNA finds and binds to the 
target DNA and the Cas9 enzymes cut it at its two ends.28 With the 
target gene excised, the cell can be induced to make a new one.29 In 
the simplest application, the CRISPR mechanism finds and cuts 
out a “defective” gene—for example, one that causes a single-gene 
disease such as cystic fibrosis, hemophilia, or sickle cell disease—
and the cell replaces it with a normal one.30 CRISPR technology 
can also be used to introduce a new gene into the space.31 
CRISPR represents a major advance over previous editing 
technologies in terms of efficiency and accuracy.32 CRISPR was 
used in the ethically contentious Chinese experiments and is now a 
primary tool in a global research effort, with projects ranging from 
basic science to plant and animal research to early efforts to apply 
it in human medicine. To illustrate, a recent survey of published 
CRISPR developments by a Spanish research institute lists the 
correction of a gene responsible for Duchenne muscular dystrophy 
in humans and mice, and—all in mouse models—improvements in 
progeria (premature aging disease), correction of a gene that causes 
obesity, and the development of a new cancer strategy that uses 
CRISPR and immunotherapy (stimulating the body’s natural 
defenses).33 Similarly, at a July 2020 virtual conference of genome 
editing scientists, industry representatives, and government 
regulators organized by the Genome Writers Guild, a 
                                                 
 26 Plumer et al., supra note 15. 
 27 Id. 
 28 Id. 
 29 Id. 
 30 Id. 
 31 See Zimmer, supra note 13. 
 32 See Conley, supra note 9, at 1047. 
 33 Lucia Gomez-Tatay, CRISPR Promises: Some of the Most Recent 
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self-described “genome engineering society”34 (which members of 
the research group attended), the use of CRISPR was discussed in 
sessions on animal and plant editing developments, editing repair, 
gene and cell therapies, many of which are now in human use, and 
the use of oncolytic (cancer-cell-killing) viruses.35 
A final and highly important technical point is the distinction 
between germline and somatic cell editing. The genetic information 
in somatic cells—the cells that make up nonreproductive organs and 
tissues—cannot be passed down to future generations. Germline 
cells are the reproductive cells (eggs and sperm) in adults, which 
do pass along parental genetic information, and the cells in 
undifferentiated early embryos, which provide the genetic 
instructions for all the subsequent cells in the body, including the 
reproductive cells. Thus, germline edits, like natural mutations, are 
transmitted to future generations. For this reason, while concerns 
about editing somatic cells are focused on the individual patient, 
germline edits also raise concerns for future generations. 
III.  THE CATEGORIES OF GENOME EDITING AND THE NEED FOR 
GOVERNANCE 
As noted above, current genome-editing governance is, at 
most, a patchwork of national and local laws, many of which apply 
only by implication, together with initiatives of many advisory and 
advocacy groups.36 Across this patchwork, one widespread point of 
early consensus is that gene editing research should prioritize 
medical applications over attempts to enhance human traits, given 
the moral concerns—such as exacerbating background social 
injustices—the latter would raise.37 Underlying this consensus is a 
broadly accepted distinction between gene editing for treatment or 
prevention of disease and disability, on the one hand, and 
                                                 
 34 GENOME WRITERS GUILD, https://www.genomewritersguild.org/ 
[https://perma.cc/59YQ-YFDM]. 
 35 GWG 2020 Conference Program, GENOME WRITERS GUILD, 
https://www.genomewritersguild.org/gwgcon2020program [https://perma.cc/FU97-
Z8FD].  
 36 See Brokowski, supra note 1 and accompanying text. 
 37 See Brokowski, supra note 1. 
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enhancement of traits generally regarded as “normal,” on the 
other.38 
On the whole, genetics professionals39 and the public40 seem to 
concur with this consensus. However, some policy statements have 
expanded the definition of “medical applications” beyond the 
categories of disease treatment or prevention, further complicating 
the issue.41 Moreover, few of the policy initiatives have offered 
specific suggestions for how science policy should deal with 
research governance issues. 
Other forms of biomedical enhancement already illuminate 
multiple ways in which using human gene editing to prevent 
disease could open the door to enhancement applications. For 
example, compensatory enhancements like immunizations 
intentionally strengthen particular human functions beyond a 
typical baseline in order to counteract pathogenic threats.42 They 
are generally not controversial, but can become so if used in such 
                                                 
 38 The consensus about this distinction has its origins in the governance of 
pre-gene editing human gene therapy. See generally Eric Juengst, The NIH 
“Points to Consider” and the Limits of Human Gene Therapy, 1 HUMAN GENE 
THERAPY 425 (1990); Eric Juengst & LeRoy Walters, Ethical Issues in Human 
Gene Transfer Research, THE DEVELOPMENT OF HUMAN GENE THERAPY 691, 
691–713 (Theodore Friedmann ed., 1999) (both sources illustrating the 
development of the consensus in the pre-gene editing environment). 
 39 See Alyssa Armsby et al., Survey Results: Genetics Specialists’ Views on 
Genome Editing, EUREKALERT (Oct. 19, 2017), https://www.eurekalert.org/ 
pub_releases/2017-10/asoh-srg101117.php [https://perma.cc/6WF3-FQD7]. 
 40 See U.S. Public Opinion on the Future Use of Gene Editing, PEW RSCH. 
CTR. (July 26, 2016), https://www.pewresearch.org/science/2016/07/26/u-s-public-
opinion-on-the-future-use-of-gene-editing/ [https://perma.cc/VY6U-TY6X]. 
 41 See generally, e.g., NETHERLANDS COMM’N ON GENETIC MODIFICATION, 
EDITING HUMAN DNA: MORAL AND SOCIAL IMPLICATIONS OF GERMLINE 
GENETIC MODIFICATION (2017), https://cogem.net/app/uploads/2019/07/Germline-
Modification1.pdf [https://perma.cc/R35E-T88E]; Genome Editing and Human 
Reproduction: Social and Ethical, NUFFIELD COUNCIL ON BIOETHICS (2018), 
https://www.nuffieldbioethics.org/publications/genome-editing-and-human-
reproduction [https://perma.cc/VK5K-FGKV] (both sources reflecting an 
expanded definition of “medical” applications). 
 42 See Anita Silvers, Meliorism at the Millennium: Positive Molecular 
Eugenics and the Promise of Progress without Excess, in MUTATING CONCEPTS, 
EVOLVING DISCIPLINES: GENETICS, MEDICINE, AND SOCIETY 215–34 (L.S. 
Parker & Rachel A. Ankeny eds., 2002). 
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practices as the U.S. military’s efforts to produce a 
“[m]etabolically [d]ominant [s]oldier” who can go “for days with 
little or no food[.]”43 Another category, secondary enhancements, 
is illustrated by the efforts of biogerontologists to develop ways of 
controlling human senescence in order to prevent late-life 
diseases.44 Once again, the basic uses are noncontroversial, but 
those efforts could also extend the healthy human life span beyond 
its historical limits, raising concerns about the value of the 
traditional human life cycle.45 In other cases, interventions that 
could forestall disease in at-risk patients might also be used 
off-label to enhance functional traits in healthy individuals.46 For 
example, synthetic human growth hormone was developed to help 
prevent extreme short stature due to hormonal deficiencies, but 
ethical questions arose about its use to enhance the height of 
hormonally typical young people.47 Finally, interventions designed 
to enhance particular traits are sometimes rationalized as 
therapeutic or preventive—that is, medicalized—in order to justify 
their development as biomedical tools; the medical rationale for 
purely cosmetic breast enhancement surgery is a classic example.48 
                                                 
 43 See William Matthews, Supersoldiers: Can Science and Technology 
Deliver Better Performance?, ARMY MAG. (Apr. 20, 2015), 
https://www.ausa.org/articles/supersoldiers-can-science-and-technology-deliver-
better-performance [https://perma.cc/7G7P-DQ39]. 
 44 See James L. Kirkland, The Biology of Senescence: Potential for Prevention 
of Disease, 18 CLINICS GERIATRIC MED. 383, 394 (2002). 
 45 See generally A WORLD GROWING OLD: THE COMING HEALTH CARE 
CHALLENGES (DANIEL CALLAHAN, RUUD H. J. TER MEULEN & EVA TOPINKOVÁ 
EDS., 1995) (describing the cross-disciplinary challenges and issues of an aging 
population). 
 46 For a discussion of this issue in a non-genetic context, see Lisa E. Smilan, 
The Off-Label Loophole in the Psychopharmacologic Setting: Prescription of 
Antipsychotic Drugs in the Nonpsychotic Patient Population, 30 HEALTH 
MATRIX: THE J. OF L. MED. 233 (2020). 
 47 See SHEILA M. ROTHMAN & DAVID J. ROTHMAN, THE PURSUIT OF 
PERFECTION: THE PROMISE AND PERILS OF MEDICAL ENHANCEMENT 16–17 
(2003). Ethical questions have also been raised about the use of growth hormone 
to prevent extreme short stature because of the normative implications of 
“heightism.” In that case, however, the concern is less with enhancement than 
with the underlying social norms themselves. 
 48 See Linda F. Hogle, Enhancement Technologies and the Body, 34 ANN. 
REV. ANTHROPOLOGY 695, 700 (2005). 
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Since the 1980s, bioethicists have used cases of enhancement 
like these to mount or refute arguments about whether 
enhancement interventions can ever be meaningfully distinguished 
from medical applications.49 They have asked whether these cases 
raise any moral concerns,50 and what societal responses they 
warrant.51 But however one resolves these ethical debates, they 
leave unanswered another question at the level of research 
governance: even if stakeholders generally accept both the 
conventional treatment-enhancement boundary and the endorsement 
of prevention as a legitimate goal for gene editing, how should 
governance policy deal with the resulting incidental enhancement 
concerns? More specifically, how should policymakers deal with 
apparent enhancements that are unintended side effects—“off-label” 
uses that are compensatory in one context but not in another—or 
otherwise tread the line between prevention, treatment, and 
enhancement? To answer this, those engaged in developing 
responsible governance for gene editing research need to know 
more about the contexts of this research, the moral meaning of 
enhancement in those contexts, and its salience as a boundary 
marker for gene editing research. It is to such issues that the 
research project and this Article are addressed.  
IV.   THE RESEARCH PROJECT 
The Authors began their collaborative research in 2018, and in 
May 2020 they received a four-year grant from the National 
Human Genome Research Institute (part of the National Institutes 
of Health) to support an intensive, multidisciplinary research 
effort.52 The research group’s members come from bioethics, 
                                                 
 49 See Eric T. Juengst, Can Enhancement Be Distinguished from Prevention in 
Genetic Medicine?, 22 J. MED. & PHIL. 12, 134–36 (1997). 
 50 See JOHANNN A.R. RODUIT, THE CASE FOR PERFECTION: ETHICS IN THE AGE 
OF HUMAN ENHANCEMENT 71–86 (2016). 
 51 See MAXWELL J. MEHLMAN, THE PRICE OF PERFECTION: INDIVIDUALISM 
AND SOCIETY IN THE ERA OF BIOMEDICAL ENHANCEMENT 185–210 (2009). 
 52 Project Information: 1R01HG010661-01A1, NAT’L INST. HEALTH, 
https://projectreporter.nih.gov/project_info_description.cfm?aid=9967484&icde
=52225919&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pbal
l= [https://perma.cc/AZ7A-MTN7] (last visited Nov. 2, 2020). 
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anthropology, sociology, law, philosophy, and public policy. A 
major component of the method is ethnographic, relying on 
interviews, participant observation at relevant events, and 
monitoring the public activities of governmental bodies and 
nongovernmental interest groups. The research also includes 
ongoing Internet and literature research and policy analysis. 
In order to ground the project’s understanding of the critical 
ethical and policy issues in a scientific perspective, the researchers 
have begun to identify and interview scientists whose work is 
relevant to gene editing. They are identifying scientists through 
monitoring the emerging literature as well as websites, email 
listservs, and other online sources; participant observation53 at 
conferences and meetings; opportunistic follow-up with colleagues 
and associates of people being interviewed; and consultation with a 
group of global advisors to the project. Using both quantitative and 
qualitative interpretive analytical methods, the research group is 
seeking to identify the conceptual points, ethical arguments, and 
policy considerations that are emerging as the greatest concerns in 
the scientific community. 
At the same time, the research is also focusing on groups that 
are beginning to consider how gene editing should be governed. 
These include government-sponsored organizations such as the 
National Academies of Sciences, Engineering, and Medicine’s 
Human Genome Editing Initiative in the United States and its 
international counterparts;54 government-sponsored international 
groups such as the World Health Organization;55 and private, 
voluntary groups advocating for various kinds of self-governance, 
such as the Association for Responsible Research and Innovation 
                                                 
 53 Participant observation is an anthropological method. As the phrase 
suggests, it involves immersing oneself to the maximum extent possible in the 
activities of the group being studied, simultaneously observing and participating 
in those activities. For a fuller explanation and an example of the method 
used in another bioethical context, see John M. Conley et al., Is Real-Time 
ELSI Realistic?, 11 AM. J. BIOETHICS EMPIRICAL 134, 136–37 (2020), 
https://doi.org/10.1080/23294515.2020.1722289 [https://perma.cc/AD9E-KEUY]. 
 54 See infra notes 64–72 and accompanying text. 
 55 See infra notes 78–79, 129–31 and accompanying text. 
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in Genome Editing (ARRIGE) and the Genome Writers Guild.56 
For such groups, the researchers are collecting relevant 
information from websites, published documents, and listserv 
emails; and engaging participant observation of their meetings and 
conferences. In the analysis of their respective views and 
approaches, the primary focus is on governance proposals relevant 
to the scientific issues identified above. The project’s ultimate 
objective is to develop useful guidance for governance that is 
particularly attentive to the policy trade-offs between preventive 
benefits and enhancement concerns. 
In the sections that follow, the Authors outline some of the 
major themes that are emerging in the research to date and map 
these themes onto some of the relevant governance literatures. The 
Article concludes with some preliminary recommendations about 
policy. 
V.   APPROACHES TO GOVERNING HUMAN GENOME EDITING 
RESEARCH 
In the relevant literatures and the project’s research to date, 
governance discussions have centered on some combination of 
four basic approaches to regulating or guiding gene editing 
research. One possibility is self-regulation, in this case by the 
scientific community—the loosely connected network of scientists 
who are working, directly or indirectly, on genome editing and its 
applications. Self-regulation can rely on nothing more than 
advisory or aspirational ethical codes or—as in the case of the 
traditional professions like medicine or law—can involve the 
authority, delegated by government, to create barriers to entry 
(licensing requirements, for example) and discipline noncompliant 
members. Two other approaches involve “hard” regulation, 
defined as rules of law imposed by and enforceable by 
governments. The imposition of hard regulation can take place at 
the level of the individual nation-state or at the international level. 
In the latter case, national governments, usually acting by treaty, 
can imbue an existing supranational organization with regulatory 
power or create a new one for a specific purpose. As the Authors 
                                                 
 56 See infra notes 74–76, 99–100 and accompanying text. 
DEC. 2020] Regulating Human Genome Editing 121 
will argue, the success of any international regime always comes 
down to the will of the participating states. The last approach is a 
hybrid. Called variously soft, polycentric, anticipatory, or new 
governance (perhaps the most widely used term, which this Article 
uses), its hallmark is a diffusion of rights and responsibilities among 
networks of state and non-state stakeholders—governments, 
corporations, non-governmental organizations (“NGOs”), and 
others—that transcend national boundaries. 
In the presentation and discussion of these governance 
approaches in the ongoing wave of declarations and reports on 
human genome editing, three sets of stakeholder concerns emerge 
as particularly prominent: (1) threats to the gene editing scientific 
community’s privileged standing as a self-governing professional 
community; (2) worries about developing hard forms of 
governance having the force of law at the international level; and 
(3) anxieties about public support for, and trust in, the human 
genome editing research enterprise. When these concerns are 
mapped onto each of the main governance approaches, the reasons 
for its widespread endorsement as an approach to gene editing 
governance become apparent.  
A. Threats to Scientific Self-Governance 
 Genome scientists, like other technical experts and 
members of traditional professions, have enjoyed wide latitude in 
governing their own work in exchange for voluntary adherence to 
expected norms of behavior.57 The rationale for this “grand bargain” 
between science and society is that socially beneficial knowledge is 
produced and applied more efficiently if scientists are granted 
professional autonomy.58 That model is under pressure today, 
however, as the professional role of scientists in high-income 
countries becomes more market-oriented.59 At the same time, 
                                                 
 57 For an early overview, see ANDREW ABBOTT, THE SYSTEM OF 
PROFESSIONS: AN ESSAY ON THE DIVISION OF EXPERT LABOR (1988). 
 58 The “grand bargain” theory is explained and criticized in RICHARD 
SUSSKIND & DANIEL SUSSKIND, THE FUTURE OF THE PROFESSIONS: HOW 
TECHNOLOGY WILL TRANSFORM THE WORK OF HUMAN EXPERTS 9–45 (2015). 
 59 As evidence of this shift, one need to look no further than the proliferation of 
technology transfer offices in U.S. universities, designed in part to help university 
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especially in China, the alleged role of scientists as agents of the 
state presses the grand bargain model from the other direction, 
raising concerns about nationalistic influences on research.60 
Concerns about threats to scientific self-governance have 
emerged in the discussion of human genome editing since the 
initial calls for moratoria on human germline interventions by 
groups of individual scientists.61 Thus, some prominent senior 
scientists who were active in recombinant DNA research in the 
1970s have tried to frame the current debate as one best managed 
by the scientific community itself.62 They sometimes invoke the 
iconic 1974 Asilomar Conference, where scientists, physicians, 
and lawyers discussed the potential risks of early recombinant 
DNA technology and produced a set of voluntary guidelines.63  
These concerns have also surfaced in the initiatives organized 
by national science academies. For example, the revelation of 
human embryo editing experiments in China came just before the 
2018 Second International Summit on Human Gene Editing in 
Hong Kong, which was sponsored by the U.S. National Academies 
of Science, Engineering and Medicine (NASEM) and its 
counterparts in the U.K. and Hong Kong.64 He Jiankui, the Chinese 
scientist who conducted those experiments, had been scheduled to 
                                                                                                             
scientists bring their invention to the for-profit private sector. At UNC-CH, for 
example, this office is called the Office of Technology Commercialization. UNC 
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 60 See, e.g., Nidhi Subbaraman, US Investigations of Chinese Scientists Expand 
Focus to Military Ties, NATURE (2020), https://www.nature.com/articles/d41586-020-
02515-x [https://perma.cc/PBK3-8W3D]. 
 61 See infra note 76 and accompanying text. 
 62 See, e.g., Comm. on Sci., Tech., & L. Pol’y & Glob. Affairs, International 
Summit on Human Gene Editing: A Global Discussion, NAT’L ACADS. PRESS 4–6 
(Dec. 1–3, 2015), https://www.nap.edu/read/21913/chapter/1 [https://perma.cc/SH9R-
279M]. 
 63 See e.g., Paul Berg et al., Summary Statement of the Asilomar Conference 
on Recombinant DNA Molecules, 72 PROC. NAT’L. ACADS. SCI. 1981 (1975). 
 64 See Nat’l Acads. of Sci., Eng’g, & Med., Second International Summit on 
Human Genome Editing: Continuing the Global Discussion, NAT’L ACADS. PRESS 
(Jan. 10, 2019), https://www.nap.edu/read/25343/chapter/1 [https://perma.cc/K8UV-
AYT4]. 
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speak on different work.65 When the embryo editing came to light, 
He was given his own session, which played out amid great tension 
and critical questioning from the audience.66 In the aftermath of 
this drama, the organizing committee nonetheless put out a 
statement that attempted to straddle the line between regulation 
and scientific freedom. On the one hand, it labeled the human 
germline genome-editing experiments as “unexpected and deeply 
disturbing,” with “flaws” ranging from study design to “failure to 
meet ethical standards,” echoing a rogue science theme; on the 
other hand, it defended professional autonomy by arguing for the 
creation of “a rigorous, responsible translational pathway toward 
[germline genome-editing] trials.”67  
The organizing committee also called for “an ongoing 
international forum” to address genome-editing governance, which 
was launched as the International Commission on Clinical Use of 
Heritable Human Genome Editing.68 The Commission released its 
report, Heritable Human Genome Editing, at a webinar on 
September 3, 2020.69 The members of the Commission stressed 
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 66 See id. One of the co-authors attended and observed. 
 67 Statement by the Organizing Committee of the Second International 
Summit on Human Genome Editing, NAT’L ACADS. SCI., ENG’G, & MED. 






 68 Id.; see International Commission on Clinical Use of Human Germline 
Genome Editing, NAT’L ACADS. OF SCI., ENG’G, & MED, http://www.nationalacademi
es.org/gene-editing/international-commission/index.htm?_ga=2.267074126.19190164
42.1562599670-715002107.1562599670 [https://perma.cc/E3CF-FKTD] (last visited 
Sept. 25, 2020). 
 69 NAT’L ACADS. OF SCI., REPORT SUMMARY: HERITABLE HUMAN GENOME 
EDITING (2020), https://www.nap.edu/resource/25665/Heritable%20Human%20Geno
me%20Editing%20Report%20Summary%20-%20FINAL%2020200903.pdf 
[https://perma.cc/96TK-PSLJ]. The webinar is available at the International 
Commission on the Clinical Use of Human Germline Genome Editing webpage. 
International Commission on Clinical Use of Human Germline Genome Editing, 
NAT’L ACADS. OF SCI., ENG’G & MED., https://www.nationalacademies.org/our-
work/international-commission-on-the-clinical-use-of-human-germline-genome-
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that no applications should be undertaken until scientists can 
“efficiently and reliably” edit human embryos without off-target 
effects, and that science is not yet at that point.70 Looking ahead, 
the Commission members proposed a ranking system for potential 
uses, with the highest priority being serious monogenic (caused by 
a single gene) conditions for people who could not have a healthy 
biological child through current embryo selection technology and 
the lowest being enhancement addressed to non-disease traits, 
using HIV resistance as an example. Although the report offers 
recommendations for a “translational pathway” to heritable human 
genome editing (“HHGE”) that have significant legislative and 
regulatory implications for both nations and international bodies, 
the International Commission is at pains to present itself as 
primarily an exercise in professional self-governance by the 
scientific community.71 As the report says, while “the decision to 
permit the clinical use of HHGE and, if so, for which specific 
applications, must ultimately rest with individual countries 
following informed societal debate of both ethical and scientific 
considerations,” the goal is “to elaborate national and international 
mechanisms necessary for appropriate scientific governance of 
HHGE, while recognizing that additional governance mechanisms 
may be needed to address societal considerations that lie beyond 
the Commission’s charge.”72  
B. Hopes and Fears for Hard Approaches to International 
Governance 
There is currently no international hard (imposed by 
governments and having the force of law) regulation of human 
genome editing or its medical applications.73 One organization that 
                                                                                                             
editing (last visited Nov. 16, 2020). Some of the co-authors attended the 
webinar. 
 70 NAT’L ACADS. OF SCI., REPORT SUMMARY: HERITABLE HUMAN GENOME 
EDITING, supra note 69, at 3. 
 71 Id. at 1–2. 
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 73 For a survey of the regulatory landscape, see R. Alta Charo, The Legal and 
Regulatory Context for Human Gene Editing, ISSUES SCI. & TECH., 
https://issues.org/the-legal-and-regulatory-context-for-human-gene-editing/ 
[https://perma.cc/FY2P-D79Y]. 
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has advocated an international law approach is ARRIGE, 
mentioned above.74 ARRIGE is a nongovernmental organization 
founded in France in 2018 whose objectives include “promot[ing] 
a global governance of genome editing through a comprehensive 
setting for all stakeholders” and “foster[ing] the development of 
genome editing technologies within a safe and ethical 
framework.”75 It has also advocated an international law approach. 
In December 2018, ARRIGE proposed: 
[T]he modification of any UNESCO universal declarations, such as the 
Declaration on the Human Genome, to include a simple additional 
point clearly stating that the application of human genome edited 
technologies should not be permitted nor authorized until deemed safe 
and effective for human beings, with precise therapeutic applications 
justified after a broad and open debate.76 
In a comparable but narrower initiative, a group of fifteen 
individual international researchers argued for a moratorium on 
germline genome editing in Nature in March 2019, calling “for the 
establishment of an international framework in which nations, 
while retaining the right to make their own decisions, voluntarily 
commit to not approve any use of clinical germline editing unless 
certain conditions are met.”77 
Another initiative that may point in the direction of harder 
forms of governance at the international level is the aspiration of 
the Expert Advisory Committee of the World Health Organization 
to develop global standards for governance of genome editing that 
could ultimately be turned into law. In 2019, the Expert Committee 
proposed a central, worldwide registry of ongoing human genome 
                                                 
 74 About Us, ASS’N FOR RESPONSIBLE RSCH. & INNOVATION IN GENOME EDITING, 
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editing research.78 But, more recently, the Expert Committee has 
published a draft framework for governance.79 As the Authors will 
discuss below, the draft has turned toward a new governance 
approach that includes an array of governmental and 
nongovernmental stakeholders.80 
Given the difficulties of developing and implementing hard 
governance approaches at the international level, some 
country-based policy efforts have focused on articulating hard 
rules at the national level. In the United States, much of the 
discussion on new hard regulatory approaches to genome editing 
has been driven by NASEM, a co-sponsor of the 2018 Hong Kong 
conference discussed above.81 Although the National Academies 
are private nonprofit organizations, they date back to a 
congressional charter signed by Abraham Lincoln and are in that 
sense government-related public organizations. In its 2017 report, 
Human Genome Editing: Science, Ethics, and Governance, 
NASEM recommended that existing regulatory processes be 
applied to basic laboratory research and to somatic human genome 
editing to treat or prevent disease or disability.82 It further 
recommended against permitting human genome editing for 
enhancement purposes, defined as “purposes other than treatment 
or prevention of disease and disability.”83 Finally, NASEM 
recommended that clinical trials of germline gene editing be 
permitted, but “limited to only the most compelling circumstances 
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 79 Expert Advisory Comm. on Developing Glob. Standards for Governance 
and Oversight of Hum. Genome Editing, Human Genome Editing: A DRAFT 
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 80 See infra notes 128–30 and accompanying text. 
 81 See supra notes 64–66 and accompanying text. 
 82 NAT’L ACADS. OF SCI., ENG’G, & MED., HUMAN GENOME EDITING: SCIENCE, 
ETHICS, AND GOVERNANCE 185 (2017). For a regulatory survey, see Brokowski, supra 
note 1, at 116–20. 
 83 NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 82, at 192. 
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and subject to a comprehensive oversight framework.”84 that 
satisfies ten rigorous criteria.85 Immediate reactions to the report 
focused on this final recommendation, which one journalist 
characterized as a “yellow light to human embryo editing.”86 
Conferences representing the broader scientific community 
reflect a more skeptical view of top-down governance, with 
governmental authorities imposing binding rules. For example, at 
the 2018 CRISPRcon conference (which members of the research 
group attended), where “a broad selection of diverse voices [came] 
together to discuss the future of CRISPR and related gene editing,”87 
real-time audience polling indicated that the audience viewed 
international regulation (presumably of the hard variety) of 
germline editing as having high importance but low feasibility. 
Various speakers emphasized the difficulties of making and 
enforcing treaties and the fragmentary, often ill-suited nature of 
existing national regulations; instead, many stressed local 
regulation, voluntary attention to local communities, and scientific 
guidelines. A significant theme was the danger of regulatory 
arbitrage: in a world that relies on government regulation, risky 
research will seek out the least-regulated environment—at the 
moment, China.88 
At the 2018 Genome Writers Guild conference,89 project 
members in attendance heard a speaker argue that “regulation will 
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 86 Jocelyn Kaiser, U.S. Panel Gives Yellow Light to Human Embryo Editing, 
SCI. MAG. (Feb. 14, 2017, 11:00 AM), https://www.sciencemag.org/news/2017/02/us-
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drive creative people underground.” Another suggested that efforts 
to increase consumer confidence in genome editing might lead to 
“reducing regulatory barriers.” At the same conference in 2020, 
speakers continued the theme that research might gravitate toward 
countries with minimal regulation. Lluis Montoliu, the current 
president of ARRIGE, stated that in the European Union (“EU”), 
“unfortunately,” edited organisms are treated as genetically 
modified organisms (“GMOs”) and are thus presumptively 
forbidden; with “progress blocked” in the EU, research goes 
elsewhere.90 In a different vein, at the 2020 World Congress of 
Bioethics, a bioethicist from the National University of Singapore 
noted that lax regulation can lead to gene editing “tourism.”91 
Consequently, he stressed, there is a strong need for global 
governance to overcome narrow national interests. Nonetheless, 
“national interest can be leveraged in global governance”—being 
saddled with a “rogue” reputation can be a meaningful sanction, as 
China has learned from the He experiments.92  
C. New Governance and Public Trust 
A third dominating theme from these early discussions has 
been the importance of transparent and publicly engaged 
approaches to governance to encourage wider trust in genomic 
science. Almost all the major policy declarations, organizational 
platforms, and promotional conference rhetoric reflect a deep 
concern for public opinion, by advocating increased public 
engagement and seeing a need for societal consensus in any 
governance development process.93 For example, one of the first 
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scientific declarations (from 2015) about human genome editing 
concludes that it would be “irresponsible to proceed” with 
germline or enhancement applications until “there is broad societal 
consensus about the appropriateness of the proposed application.”94 
And, as co-author Eric Juengst has pointed out about the 2017 
NASEM Report: 
Fully half of the report’s fourteen formal recommendations reiterate the 
need for public dialogue to drive the policy making process, using a 
family of phrases variously calling for “broad,” “extensive,” 
“inclusive,” “transparent,” “meaningful,” “expanded,” “robust,” and 
“ongoing” public “communication,” “discussion,” “debate,” 
“engagement,” “input” and “participation,” as a “necessary condition 
for moving forward” before “any consideration of whether to authorize 
clinical trials” of either enhancing or inheritable human gene editing 
interventions. 95 
But others caution that public engagement may not help 
advance the goal of more harmonized and publicly trustworthy 
governance, especially internationally, because of the dramatic 
range of public views about the ethics of genome editing.96 This 
diversity of voices and viewpoints was on display at the 2018 
CRISPRcon conference, where the moderator of a panel of 
activists representing indigenous, disability, agricultural, and other 
constituencies concluded, “we may never reach something that is a 
consensus. It will fail to satisfy virtually everyone.”97 In a similar 
vein, at the 2020 Genome Writer’s Guild Conference, Lluis 
Montoliu, the president of ARRIGE, spoke pointedly about the 
need “to foster public trust and prove we deserve it.”98 Noting 
ARRIGE’s position regarding CRISPR, he counseled attendees to 
be honest about its current limitations and to be clear with the 
public about off-target effects (accidentally editing the wrong 
gene) and heritability concerns.99 He said—perhaps with 
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unintended irony, given science’s mixed messages during the 
pandemic—that COVID presents an opportunity to “remind 
society that science has procedures, that we have timelines, that we 
have permissions, and that we have protocols. That we need to do 
one step after the other.”100  
At the 2020 World Congress of Bioethics, a bioethicist from 
University of Manchester in the United Kingdom pursued the 
problem of public trust from a somewhat different angle.101 Starting 
from the “assumption . . . that we need public discourse,” he asked 
such questions as: “can we get relevant input,” “what’s relevant,” 
“what are relevant publics,” and “how do we get input from 
them?”102 He concluded by posing an ultimate dilemma: “what if 
the public disagrees with bioethicists in the end?” His answer was 
that “bioethicists should show humility—consensus is rare—let the 
public decide.”103 But he left unaddressed the problem he started 
with—discerning the public’s will.104  
Another related set of concerns about public trust emerged in a 
panel discussion entitled “CRISPR and Human Identity: 
Governing Germline Gene Editing” at the 2020 ELSI [referring to 
the Ethical, Legal, and Social Implications of genetics] Virtual 
Forum.105 A recurrent theme was the need for humility in dealing 
with the public. One panelist, Emory University disability scholar 
Rosemarie Garland-Thomson, warned of “velvet eugenics.” In 
contrast, she urged, the gene editing community needs to “cultivate 
an attitude of humility” toward others’ lives and avoid 
characterizing mere human variation as “new disease” that gene 
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editing can cure.106 To illustrate the point, she said that “we’re 
already practicing eugenics . . . routinely in reproductive medicine. 
For example, . . . [we’ve] already decided that the human variations, 
[like] Down Syndrome, are unacceptable variations and . . . that kind 
of person is ‘expendable’ and ‘disposable’ . . . . [W]hat a serious 
disease is, what human suffering might be, we need to look at it 
quite a bit more closely.”107  
VI. HOW WELL DO THE VARIOUS APPROACHES TO 
GOVERNANCE MEET THESE CONCERNS? 
In mapping these concerns onto relevant theories of 
governance, the researchers can begin to make some observations 
about the promise of the various approaches to governance. Table 
1 lists five goals that gene-editing stakeholders have begun to 
identify as desiderata that any effective governance regime should 
promote: scientific autonomy, international harmonization, and 
public trust, plus meaningful enforcement and ease of 
implementation. The table then rates each of four potential 
approaches to governance—professional self-governance, national 
laws, international treaty, and new governance—according to its 
apparent capacity to promote these objectives.  
A. Scientific Self-Regulation 
The potential efficacy of scientific self-regulation is largely a 
function of the details of the model chosen. Self-regulation that 
depends solely on voluntary compliance with ethical precepts is 
only as effective as participants choose to make it. At the other end 
of the spectrum, as in the case of law, it can take on many of the 
attributes of hard regulation if a government defines the profession 
and delegates to it the power to limit entry, police members’ 
conduct, and expel those who fail to comply with its rules. In the 
middle ground, a professional group can informally regulate conduct 
through such measures as public shaming (censure) and, in the 
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academic world, conditioning publication on ethical warranties.108 
This begins to look like a new governance environment, as will be 
discussed shortly. 
Voluntary professional self-governance obviously maximizes 
scientists’ autonomy and control over the scientific enterprise, and 
equally obviously does not have sharp teeth. As the model moves 
in the direction of the harder regulation of the traditional 
professions, the teeth get sharper, but at the expense of autonomy. 
International harmonization of voluntary standards is possible, but 
meaningless without international enforcement mechanisms. 
Public trust is unlikely to be affected by the mere presence of 
standards but will depend on how well the scientists behave. Since 
self-governance is so open-ended, it can be easy to implement. A 
problem with this approach, however, is that “science” has no clear 
definition as a profession; the disparate putative members include 
researchers from many disciplines as well as healthcare 
practitioners who may already be subject to hard regulation. 
B. Hard Regulation 
Hard regulation on a country-by-country basis has the virtue of 
strong enforcement potential, and the adoption of rigorous 
standards that are diligently enforced may engender public trust—
or cynicism if enforcement seems lax. But regulations take time 
and political will to adopt, and international consistency is unlikely 
on any complex legal issue. Moreover, countries may be tempted 
to adopt weaker standards to attract research, much like countries 
have used weaker environmental and labor standards to attract 
industry.109 
                                                 
 108 The death of research subject Jesse Gelsinger in a trial employing gene 
therapy, a predecessor to gene editing and still in trials today, provides an 
example where censure and conditions on publication were imposed as sanctions 
on researchers and institutions conducting research. See Sheryl Gay Stolberg, 
The Biotech Death of Jesse Gelsinger, N.Y. TIMES MAG. (Nov. 28, 1999), 
https://www.nytimes.com/1999/11/28/magazine/the-biotech-death-of-jesse-
gelsinger.html [https://perma.cc/B8UN-258R]. 
 109 See Flagging Out, GREENFACTS, https://www.greenfacts.org/glossary/def/f
lagging-out.htm [https://perma.cc/M8AB-27A6] (last visited Sept. 25, 2020). 
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Binding and enforceable international legal regimes—which 
solve the harmonization problem—are even more difficult to create 
and maintain. First, all the relevant countries—in the gene editing 
context, the United States, China, and the EU, at a bare 
minimum—must negotiate and sign a treaty. Then each signatory 
must ratify the treaty according to its national law. In some cases, 
signatory countries must enact national legislation to implement 
the treaty.110 Finally, and critically, the signatories must actually 
carry out the enforcement they have promised. The recent U.S. 
withdrawal from the Paris Agreement on climate change illustrates 
these difficulties.111 The Obama administration signed the 
Agreement but never submitted it to the U.S. Senate for ratification 
as a treaty; the Trump administration therefore treated it as a 
non-binding commitment that it was free to repudiate.112 Given all 
these obstacles, a meaningful international law of gene editing 
seems unlikely for the foreseeable future. 
The version of this approach suggested in the Nature proposal 
described above113—parallel legal action by individual countries—
avoids some of the formal steps required by the NASEM 
Commission report, Heritable Human Genome Editing, with its 
recommendation of nation-level action guided by its “translational 
pathway.”114 Leaders of essential countries must come to an 
agreement on general principles and the manner of implementation, 
                                                 
 110 Treaties that require implementing legislation are called non-self-executing 
treaties, in contrast to self-executing treaties, which do not. See Self Executing 
Treaties, LEGAL INFO. INST., https://www.law.cornell.edu/wex/self_executing_tr
eaty#:~:text=A%20self%2Dexecuting%20treaty%20is,through%20the%20impl
ementation%20of%20legislation [https://perma.cc/D88V-UXBS] (last visited Sept. 
25, 2020). 
 111 See Press Statement, Sec’y of State Michael R. Pompeo, On the U.S. 
Withdrawal from the Paris Agreement (Nov. 4, 2019) (on file with the U.S. 
Dept. of State). 
 112 See Eugene Kontrovich, The U.S. Can’t Quit the Paris Climate 




 113 See Lander et al., supra note 77 and accompanying text. 
 114 See NAT’L ACADS. OF SCI., REPORT SUMMARY, supra note 69. 
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and then—at least in democracies—persuade potentially fractious 
lawmakers to go along. 
C. New Governance  
This leaves the hybrid approach that combines aspects of 
self-governance with elements of harder regulation. The 
still-nebulous proposals for a hybrid approach to governance that the 
project has encountered can be grouped under the broad heading of 
new governance.115 According to new governance theory, the 
democratic state is in the midst of a shift to a “post-regulatory” 
model characterized by a weakening of top-down regulation by the 
all-powerful administrative state—“old” governance—in favor of a 
diffusion of rights and responsibilities among governments, private 
companies, NGOs, and other interested parties.116 New governance 
approaches involve “transnational private regulation” by coalitions 
of non-state actors.117 The essence of the post-regulatory state, 
captured in the linguistic shift from government to governance, is 
the distribution of regulatory power among transnational networks 
of state and non-state actors that often use market and other private 
forces to set and enforce standards.118 
                                                 
 115 Recent articles have reviewed new governance theory in a variety of 
contexts. See, e.g., John Gerard Ruggie, Global Governance and “New 
Governance Theory”: Lessons from Business and Human Rights, 20 GLOB. 
GOVERNANCE 5 (2014); Myrisha S. Lewis, Innovating Federalism in the Life 
Sciences, 92 TEMP. L. REV. 383 (2020); Melanie Hess, A Call for an International 
Governance Framework for Human Germline Gene Editing, 95 NOTRE DAME L. 
REV. 1369 (2020); Ryan Hagemann, Jennifer Huddleston Skees & Adam Thierer, 
Soft Law for Hard Problems: The Governance of Emerging Technologies in an 
Uncertain Future, 17 COLO. TECH. L.J. 37 (2018); Jonas J. Monast, Editing 
Nature: Reconceptualizing Biotechnology Governance, 59 B.C. L. REV. 2377 
(2018). 
 116 See John M. Conley & Cynthia A. Williams, Engage, Embed, and Embellish: 
Theory versus Practice in the Corporate Social Responsibility Movement, 31 J. 
CORP. L. 1, 6, 31–33 (2005) (defining attributes of new governance). 
 117 Tim Bartley, Institutional Emergence in an Era of Globalization: The Rise 
of Transnational Private Regulation of Labor and Environmental Conditions, 
113 AM. J. SOCIO. 297, 297 (2007). 
 118 See Conley & Williams, Engage, Embed, and Embellish, supra note 116, 
at 31. 
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There have been extensive studies of new governance 
approaches in other areas that are analogous in important respects 
to gene editing research. One example is the corporate social 
responsibility movement.119 In that instance, many corporations 
have sought to address social and environmental issues by such 
strategies as voluntary commitments to industry codes and best 
practice standards, convening multi-stakeholder advisory groups 
(sometimes adding such constituencies to their boards of directors), 
and measuring and disclosing social and environmental risks 
through triple bottom line (financial, social, and environmental) 
accounting.120 Such private governance networks sometimes adopt 
substantive standards promulgated by governmental and 
quasi-governmental bodies. For example, the biggest global banks 
collectively adopted the World Bank’s social and environmental 
standards in establishing the “Equator Principles” to govern private 
lending for large-scale projects in developing countries.121 
Motivations for participating in new governance regimes can 
vary.122 Private actors may perceive a hard regulation vacuum and 
move to fill it in the sincere belief that standards must be set. But 
they may also see an opportunity to preempt more onerous 
governmental regulation by demonstrating, at least superficially, 
that they have the problem under control. With respect to efficacy, 
new governance advocates sometimes contend that actors who 
invest in the creation of standards are more likely to comply than 
those who have standards imposed on them. Especially where 
science, technology, and other arcane practices are involved, 
private actors can plausibly contend that those who know the 
                                                 
 119 See generally id.; John M. Conley, Cynthia A. Williams, Lodewijk 
Smeehuijzen & Deborah E. Rupp, Can Soft Regulation Prevent Financial 
Crises?: The Dutch Central Bank’s Supervision of Behavior and Culture, 51 
CORNELL INT’L L.J. 773 (2019) (both sources explaining and illustrating 
corporate social responsibility movement). 
 120 See Conley & Williams, Engage, Embed, and Embellish, supra note 116, 
at 2–5. 
 121 See generally Conley & Williams, Global Banks as Global Regulators, 
supra note 8 (providing analysis of adoption of Equator Principles). 
 122 See id. at 558–62 (reviewing evidence for many of these motives in the 
banking context). 
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practice best are most qualified to set the standards.123 But it is also 
possible that the outcome will be mere window dressing—weak 
and easily evaded standards that can nonetheless be sold to 
lawmakers and other relevant audiences.124 Likewise, meaningful 
enforcement mechanisms can also be difficult to construct in the 
absence of governmental authority.125 A central tenet of the 
corporate social responsibility movement, for example, is that 
investors and consumers, informed by adverse publicity and triple 
bottom line reporting, will become aware of noncompliance and 
penalize laggards. But the evidence for this “business case” for 
compliance is inconclusive; it is unclear whether either profits or 
share performance correlate with indicators of social responsibility.126 
One can readily envision such a governance network arising 
with respect to CRISPR genome editing—indeed, the project may 
be witnessing its formative stages. Even in the absence of hard 
regulations, governmental authorities may play a role, perhaps by 
the promulgation of standards as ARRIGE has suggested.127 The 
early evidence suggests that other key actors are likely to be 
scientists; NGOs; interested for-profit corporations and their 
principals; scientific gatekeepers including funders, journal editors, 
university officials, and voluntary scientific organizations; and 
organized voices speaking for affected communities and other 
public constituencies.128 
                                                 
 123 See John M. Conley et al., Scientific Social Responsibility: Lessons from 
the Corporate Social Responsibility Movement, 15 AM. J. OF BIOETHICS 64, 65–
66 (2015). 
 124 See Conley & Williams, Engage, Embed, and Embellish, supra note 116, 
at 13–18 (providing evidence from the corporate social responsibility context). 
 125 See id. at 20. 
 126 See Conley & Williams, Global Banks as Global Regulators, supra note 8, 
at 560–61 (reviewing “the elusive ‘business case’”); Conley & Williams, 
Engage, Embed, and Embellish, supra note 116, at 14, 21–23 (evaluating 
business case and presenting investor perspective). 
 127 See supra notes 75–76 and accompanying text. 
 128 For example, the National Institutes of Health (NIH) proposes to be a key 
actor. In April 2019, the NIH published its charter of NExTRAC (Novel and 
Exceptional Technology and Research Advisory Committee). It was created to 
review emerging biotechnologies such as gene editing and characterized as an 
updated RAC (Recombinant DNA Advisory Committee), which examined gene 
therapy research for thirty years. The agenda included updates from current 
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Depending on the actor, motivations to participate may include 
professionalism, ethics, principle, profit, self-promotion, and 
ideology; their respective contributions to the ultimate mix will 
strongly influence the quality of any standards that result. Scientific 
stakeholders may be best positioned to resolve thorny definitional 
questions such as distinguishing treatment and prevention from 
enhancement. Even in the absence of governmental sanctions, 
meaningful enforcement mechanisms could include access to 
funding and publication; academic hiring and promotion decisions; 
exclusion from important organizations; and, at the most basic 
human level, shame and obloquy versus honor and prestige. While 
these carrots and sticks can be significant, they fall short of the 
civil and criminal penalties that governments can exact. 
There is growing evidence from the research to date that a range 
of gene editing stakeholders are already gravitating toward the new 
governance approach. The most significant piece of evidence is the 
World Health Organization’s Expert Advisory Committee’s recently 
issued draft report.129 The report’s lengthy definition of “good 
governance” is in fact a comprehensive definition of new governance: 
Good governance is not limited to formal regulation pursuant to 
legislation or judicial opinion. Governance is a system of norms as well 
as influence, and it includes forces to shape the direction and conditions 
of research and applications, such as well-crafted public and private 
funding priorities and conditions. Good governance also includes 
professional and industrial best practices, peer review and ethics 
assurance by publishers, and health care insurance coverage decisions 
for instance. Possible liability for harmful research or clinical care is an 
indirect source of governance, mediated by liability insurance.130 
                                                                                                             
technologies, questions in defining “emerging biotechnologies,” and 
concerns about proper stakeholder engagement. See Carrie D. Wolinez, 
Introducing the NExTRAC, NAT’L INST. HEALTH (April 24, 2019), 
https://osp.od.nih.gov/2019/04/24/introducing-the-nextrac/ [https://perma.cc/Y3GB-
RPWM]; Novel and Exceptional Technology and Research Advisory Committee 
(NExTRAC) Agenda – December 5-6, NAT’L INST. HEALTH, 
https://osp.od.nih.gov/wp-content/uploads/NExTRAC_Dec_2019_Agenda.pdf 
[https://perma.cc/G2AL-U9AF] (last visited Sept. 15, 2020). 
 129 Expert Advisory Comm. on Developing Glob. Standards for Governance 
and Oversight of Hum. Genome Editing, supra note 79. 
 130 Id. 
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Similarly, its list of “tools for governance” enumerates all the 
possible mechanisms for shaping behavior that new governance 
theorists have envisioned: 
Tools for Governance: 
• Law: Declarations, Treaties, Conventions, Legislation, 
Regulation 
• Judicial rulings 
• Ministerial decrees 
• Conditions on research funding 
• Moratoria 
• Accreditation, registration, licensing 
• Professional self-regulation 
• Research ethics guidelines 
• Collaboration with publishers and conference organizers 
• Education and training of researchers and 
clinician-scientists 
• Interest groups and public influencers131 
A second recent example comes from the 2020 Genome 
Writers Guild Conference. A representative from the U.S. National 
Institute of Standards and Technology (“NIST”) emphasized the 
government’s interest in a new governance approach to gene 
editing.132 As its name suggests, NIST, which is part of the U.S. 
Department of Commerce, works with the academic and private 
sectors “[t]o promote U.S. innovation and industrial 
competitiveness by advancing measurement science, standards, 
and technology in ways that enhance economic security and 
improve our quality of life.”133 Importantly, it is not a regulatory 
agency. 
                                                 
 131 Id. 
 132 See Genome Writers Guild, supra note 90 (broadcasting the address of 
Samantha Maragh titled “A Consortium Approach to Foster Confidence in Gene 
Editing” beginning at 24:17). 
 133 NIST Mission, Vision, Core Competencies, and Core Values, NAT’L INST. 
STANDARDS & TECH. (Jan. 26, 2017), https://www.nist.gov/about-nist/our-
organization/mission-vision-values [https://perma.cc/5HKG-GER9]. 
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Samantha Maragh, the Leader of NIST’s Genome Editing 
Program,134 speaking on a panel with the odd title of “EU Regulatory 
Landscape – genome engineering and supporting the public trust,”135 
gave a presentation entitled “A Consortium approach to foster 
confidence in genome editing technology.”136 The consortium that 
NIST is sponsoring is a public-private collaboration, currently 
including thirty-seven organizations from government (most 
prominently, the USFDA), industry, academic science, and the 
non-profit sector. Its purpose, Maragh said, “meant to be enabling, 
not limiting”—specifically, its goal should be the advancement of 
gene editing technology.137 One might question whether 
“foster[ing] confidence” is anything more than a public relations 
objective or whether confidence, as opposed to safety, is an 
appropriate concern for a standard-setting body, as well as the 
absence of public voices from the consortium. But there is no 
doubt that Maragh was describing a new governance network not 
fundamentally different from the Equator Principles signatories. 
One reason that a new governance approach is being endorsed 
for gene editing research is that it can be much easier to implement 
than more traditional regulatory approaches, especially at the 
international level. As the speed with which the Equator Principles 
were adopted illustrates,138 professional and other private 
stakeholders can move quickly, and on a global scale. In every 
other category, however, the promise of a new governance 
approach to gene editing research is equivocal. If done well, it can 
certainly promote public trust, work consistently across 
international boundaries, and result in meaningful enforcement. 
Because scientists would be critical stakeholders, the categories are 
interrelated: success in one depends on corresponding success in 
                                                 
 134 Genome Writers Guild, supra note 132. 
 135 In the first place, it is unclear what it means to “support” public trust unless 
the trust is already there. In any event, none of the six speakers said anything 
about public trust. 
 136 Genome Writers Guild, supra note 132, at 24:17. 
 137 Id. at 35:42. 
 138 See Conley & Williams, Global Banks as Global Regulators, supra note 8, 
at 545 (reviewing initial adoption, revision, and rapidly growing acceptance over 
seven years). 
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the others. Thus, scientists can retain their autonomy and create 
public trust only by promoting strong standards and submitting to 
rigorous enforcement. The Equator Principles experience is again 
relevant here. It is unclear whether they really have reduced the 
adverse social and environmental impacts of large-scale projects.139 
There is widespread agreement that the participating banks have 
done a reasonably diligent job of monitoring their borrowers, but 
equally widespread concern that the adoption of the Principles may 
have driven some project sponsors to seek out non-participating 
lenders in Russia, China, and elsewhere.140 But despite this mixed 
evidence, new governance is the only approach with realistic 
potential to promote each of the objectives identified in Table 1 in 
the short to medium term. 
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Summary of the different approaches to governance and the ability of each to promote 
the enumerated priorities. 
VII. CONCLUSION 
As the embryo experiments in China illustrate, the early 
implementation of human genome editing has had a 
“ready-fire-aim” quality. Scientific self-regulation has not been 
able to anticipate events well enough to secure widespread 
                                                 
 139 See id. at 562–64 (reviewing inconclusive evidence). 
 140 See id. at 566–67. 
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international allegiance to common standards and has thus been 
relegated to clean-up responses in the wake of scandal. Regulation 
by international law is a long and contested process at best; the 
complexities of human genome editing only lengthen the odds 
against such a solution. Negotiating and implementing consistent 
nation-by-nation regulations is not much easier. This may be a 
situation where a hybrid new governance approach, despite its 
inevitable shortcomings, will be far preferable to the chaos of no 
meaningful governance at all. Early evidence suggests that the 
scientific community and its various constituencies are heading in 
this direction, with constant attention to public engagement along 
the way. Given the potential costs of doing nothing, these are 
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